Introduction
============

Colorectal cancer (CRC) is one of the most frequently occurring malignancies in the world [@B1]. In 2018, CRC accounted for more than 860,000 deaths with 1.8 million new cases [@B1]. Several risk factors contribute to CRC progression, including advancing age, chronic intestinal inflammation, and genetic aberrations/mutations [@B2]-[@B4]. Current evidence suggests that genetic contribution is about 30% [@B5]. Multiple genetic studies have shown that the single nucleotide polymorphisms (SNPs) are associated with the occurrence, development, metastasis and drug tolerance of CRC [@B6],[@B7].

The human formyl peptide receptor 1 (FPR1) belongs to the seven-transmembrane G protein-coupled receptors (GPCRs) [@B8]. FPR1 is known to have important functions in host defense and inflammation. It is expressed mainly on phagocytic leukocytes, neutrophils, and monocytes [@B8]. Binding of agonistic ligands to FPR1 results in activation of a G protein-mediated signaling cascade; leading to cell chemotaxis, calcium flux, phagocytosis, and release of inflammatory factors [@B8]-[@B10]. FPR1 has also been detected on cells of non-hematopoietic tissues such as epithelial cells, endothelial cells, and neurons [@B11]. Besides, recent evidence shows that it is expressed in several types of human cancer tissues such as gastric cancer [@B12],[@B13], lung cancer [@B14], breast cancer [@B15], etc. Our previous study revealed the high expression of FPR1 in primary human CRC tissue [@B16]. FPR1 mRNA expression was also associated with tumor serosal infiltration in CRC patients [@B16]. Human *Fpr1* is a 6-kb single copy gene and located on chromosome 19 (19q13.3) [@B8]. Several SNPs of *Fpr1* has been reported previously to be associated with blood pressure [@B17], C-reactive protein (CRP) level [@B18], E-selectin expression [@B19], and inflammatory disease such as aggressive peritonitis [@B20],[@B21]. In addition, *Fpr1* SNP (rs1042229) was also associated with stomach cancer [@B22]. However, the function of *Fpr1* SNPs in human colorectal cancer has not been investigated.

In this study, we enrolled forty-eight Chinese CRC patients. Seven *Fpr1* SNPs (c.289C\>A, c.301G\>C, c.306T\>C, c.546C\>A, c.568A\>T, c.576T\>C\>G, and c.1037C\>A) were detected. The allele and genotype frequencies of these SNPs in CRC tissues were not significantly different from that in whole blood cells derived from healthy Chinese subjects. We further examined the correlation between *Fpr1* SNPs with clinicopathological characteristics and several specific diagnostic markers of CRC.

Materials and methods
=====================

Human subjects
--------------

A total of 60 surgically resected CRC tissue specimens were obtained from Changzheng Hospital, Shanghai, China. Histological classification and stage of the CRC were determined according to the UICC TNM classification system [@B23]. Acquisition of tissue specimens was approved by the Changzheng Hospital Institution Review Board of and was carried out under guidance of established ethical protocols. Patients with colorectal cancer were between 22 and 83 years old, and colonoscopy and pathological examinations were confirmed. Exclusion criteria: (1) with a history of other tumor diseases, or with other genetic diseases; (2) severe colorectal bleeding occurred within 30 days; (3) participating in other clinical trials requiring drugs within 60 days; (4) serious cardiovascular diseases, uncontrolled infections, or other uncontrolled co-existing diseases; (5) pregnant women; (6) subjects receiving preoperative neo-adjuvant therapies and/or radiotherapy. Each patient signed the informed consent, which outlined the purpose and application of the colorectal tumor tissue that they donated. All samples were fixed with 4% paraformaldehyde and cryoprotected in 30% sucrose for immunohistochemical staining or were kept frozen at -80°C for other biochemistry analysis.

DNA isolation, Polymerase Chain Reaction (PCR) and sequencing
-------------------------------------------------------------

Genomic DNA was isolated from the CRC tissue specimens with a DNA isolation kit (GIAGEN, Hilden, Germany). To examine Fpr1 SNPs c.289C\>A, c.301G\>C, c.306T\>C, c.546C\>A, c.568A\>T, c.576T\>C\>G, and c.1037C\>A, primers were designed to amplify a 1538bp fragment of the FPR1 gene containing these SNPs. The forward primer was 5\'-TTGCCCAACAGGTACAATAA-3\' and the reverse primer was 5\'-ATTTCAGGCAAACTAGGATG-3\'. The products were sequenced with the primers 5\'-AGAACCACCGCACCGTGA-3\' and 5\'-GGATGTTCCGGCTGTTGT-3\'. PCR was performed according to the following conditions: 95 ºC for 3 min, 40 cycles of denaturation at 95 ºC for 20 s, annealing at 56 ºC for 45 s, and extension at 72 ºC for 20 s with a final extension at 72 ºC for 10 min. All samples yielded PCR products, which were sequenced by Shanghai DNA biotechnologies.

Immunohistochemistry
--------------------

The primary antibodies were mouse anti-human P53 protein and anti-human Ki67 protein (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, United States), and rabbit anti-human CEA protein and rabbit monoclonal anti-HER2 protein (1:100; IBL, Tokyo, Japan). After incubation with the primary antibody, the sections were incubated with the secondary antibody and avidin-biotin-peroxidase complex. The slides were counterstained with hematoxylin and eosin. Positivity for P53 and Ki67 were defined as nuclear staining in \> 10% of the tumor cell nuclei. Positivity for CEA was \> 10% cytoplasmic staining. HER-2 immunostaining was scored as follows: 0-no reactivity or membranous reaction in fewer than 10% of cells, (1+)-faint complete or partial membranous reactivity in more than 10% of cells, (2+)-moderate complete or basolateral membranous reactivity in more than 10% of cells, and (3+)-strong complete or basolateral membranous reactivity in more than 10% of cells. The level of HER2 membranous expression was considered positive if IHC staining was 2+ or 3+. Immunohistochemical reactivity was interpreted blindly by two independent investigators.

Data analysis
-------------

Statistical analysis was performed using the statistic software GraphPad Prism 5 (San Diego, CA). Correlations between Fpr1 SNPs and various clinicopathological characteristics and specific diagnostic markers of CRC were analyzed by the Chi-square test. P values less than 0.05 was considered statistically significant.

Results
=======

Basic clinical characteristics of the colorectal cancer patients
----------------------------------------------------------------

In this study, we enrolled 60 Chinese CRC patients, with 30 (50%) male and 30 (50%) female. Their age ranged from 22 to 83 years (mean age, 54.5 years). 36 patients had colon cancer and 24 patients had rectal cancer. All patients had T0-T4 cancers according to the TNM classification. 29 patients were classified as highly or poorly differentiated and 31 as well or moderately differentiated. Ten of these patients had distant metastasis. The basic clinical characteristics of these patients are listed in Table [3](#T3){ref-type="table"}.

Single nucleotide polymorphisms of Fpr1 in Chinese colorectal cancer patients
-----------------------------------------------------------------------------

Seven previously identified Fpr1 SNPs (c.289C\>A, c.301G\>C, c.306T\>C, c.546C\>A, c.568A\>T, c.576T\>C\>G, and c.1037C\>A) were detected in Chinese CRC patients. The c.306T\>C and c.546C\>A are synonymous SNPs and other five sites are non-synonymous SNPs. They are all located within exon 2 of the Fpr1 gene. The allele and genotype frequencies of these SNPs identified by sequence analysis of Fpr1 gene are demonstrated in Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The minor allele frequency (MAF) for c.289A (p.L97M), c.301C (p.V101L), c.306C (p.F102F), c.546A (p.P182P), c.568T (p.R190W), and c.1037A (p.A346E) were 0.115, 0.448, 0.031, 0.500, 0.135, and 0.344 respectively. The allele and genotype frequencies of these SNPs in CRC tissues were not significantly different from that in whole blood cells derived from healthy Chinese subjects. Data of healthy Chinese subjects are from Zhou\'s reports [@B24] and the HapMap resource (CHB, Han Chinese in Beijing, and CHS, Southern Han Chinese at <https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>).

Correlation of Fpr1 SNPs with clinicopathological characteristics
-----------------------------------------------------------------

Next, we examined the correlation between Fpr1 SNPs with clinicopathological characteristics which included sex, age, AJCC stage and location of tumor, tumor size, differentiation, lymphatic invasion, distant metastasis, and pathological type. The significance of association between each of the SNPs and clinicopathological characteristics was determined by Chi-square test. Significant associations were observed between genotypes of c.289C\>A and distant metastasis (P=0.001, Table [3](#T3){ref-type="table"}). Also, significant associations were observed between genotypes of c.306T\>C and tumor size (P=0.016, Table [3](#T3){ref-type="table"}). Genotypes of c.546C\>A was closer to tumor size and lymphatic invasion (P=0.012 and P=0.043, respectively, Table [4](#T4){ref-type="table"}). Meanwhile, genotypes of c.1037C\>A was related with tumor location and differentiation (P=0.000 and P=0.005, respectively, Table [4](#T4){ref-type="table"}). Besides, genotypes of c.576T\>C\>G was related with pathological type (P=0.000, Table [5](#T5){ref-type="table"}).

Furthermore, by using immunohistochemistry, we investigated some specific diagnostic markers of CRC such as P53, CEA, HER2, and Ki-67. The correlation between Fpr1 SNPs with these markers was analyzed (Table [6](#T6){ref-type="table"}). The results showed that several Fpr1 SNP positions including c.289 (C\>A) and c.576 (G\>C\>T) were related to the expression of P53 (P=0.004 and P=0.008, respectively), and c.289 (C\>A) and c.306T\>C to CEA (P=0.03 and P=0.011, respectively, Table [6](#T6){ref-type="table"}). Otherwise, genotypes of c.576T\>C\>G were also associated with HER2 (P=0.001, Table [6](#T6){ref-type="table"}). Besides, genotypes of c.289 (C\>A) and c.576T\>C\>G were related with Ki-67 (P=0.034 and P=0.001, respectively, Table [6](#T6){ref-type="table"}).

Discussion
==========

Colorectal cancer, a highly invasive carcinoma, has high rates of venous invasion, lymphatic duct invasion, and lymph node metastasis [@B25]. Metastatic colorectal cancer (mCRC) is the main cause of the death in CRC patients [@B25]. In our previous study, the expression of FPR1 has been identified to be related to tumor serosal invasion in CRC patients. FPR1 activation promoted the migration and invasion of CRC cells [@B16]. In this work, we found the patients with Fpr1 homozygous 289A genotype showed a higher risk to distant metastasis than that with the 289C/C or 289A/C genotypes (P=0.001), suggesting an association between Fpr1 genotype c.289 and the distant metastasis. In recent years, a large number of metastasis-associated genes have been identified. Via genomic DNA microarray and function annotation, Cai et al. reported that multiple SNP-associated genes specific to CRC metastasis were related to adhesion and immunity, such as cell motion, cell-substrate adhesion, regulation of innate immune response, etc [@B26]. Furthermore, many SNP-associated genes were also associated with adhesion- and immune-related signaling pathways, including adherens junction, chemokine signaling pathway, and cytokine-cytokine receptor interaction [@B26]. Otherwise, Lan and colleagues demonstrated that genetic polymorphisms of insulin-like growth factor 1 (IGF-1) and interleukin-8 (IL-8) increased susceptibility to lymph node metastasis in CRC patients [@B27]. All these data suggested that the polymorphisms of those immune-related genes play an important role in the metastasis of CRC.

As we mentioned earlier, a major cause of death in colorectal patients is metastasis [@B25]. Early clinical trials suggest the role for personalized HER2-targeted therapy in mCRC [@B28]. HER2, also known as ERBB2 or proto-oncogene Neu, is a member of the human epidermal growth factor receptor family. Amplification or over-expression of HER2 has been reported to be closely related to the development and progression in certain aggressive types of cancers including breast cancer and CRC [@B29],[@B30]. HER2 is also a potential biomarker guiding chemotherapy in advanced colorectal cancer [@B31]. Our results showed that genotypes of c.576T\>C\>G were also associated with HER2. Previous studies have found that multiple factors may influence the expression of HER2 [@B32]. Since Fpr1 SNPs are closely associated with HER1 expression in CRC patients, further experiments are needed to verify how Fpr1 SNPs regulate the expression of HER2. Besides, the relationship between Fpr1 SNPs and HER2-targeted therapy in mCRC can also be explored.

Multiple studies reported that the genetic polymorphisms are associated with the occurrence and progression of CRC [@B33],[@B34]. In this work, we found the allele and genotype frequencies of Fpr1 SNPs in CRC tissues were not significantly different from that in whole blood cells derived from healthy Chinese subjects. This result suggested that the polymorphisms of Fpr1 may have no effect on the occurrence of CRC. However, Fpr1 genotypes of c.289C\>A, c.306T\>C, c.546C\>A, c.576T\>C\>G, and c.1037C\>A showed significant associations with the tumor size in CRC patients, indicating their potential role in the progression of CRC. The polymorphism of c.576 was also reported to be associated with susceptibility to stomach cancer and periodontitis [@B21], [@B22]. These results suggest that Fpr1 polymorphisms may be closely related to the occurrence and/or development of gastrointestinal tumors.

CEA, specifically expressed in biliary and gastrointestinal epithelium, is a diagnostic marker for CRC [@B35]. Previous studies reported that the expression of CEA in CRC was related to survival [@B36]. The expression of CEA is frequently higher in poorly differentiated colon cancer [@B37]. In this study, we found that the genotypes of Fpr1 c.289 (C\>A) and c.306T\>C were highly associated with CEA expression in CRC. Further experiments are needed to verify the mechanism by which Fpr1 SNPs regulates CEA expression.

Our previous study found that the expression of FPR1 was related to tumor serosal invasion in CRC patients. FPR1 activation promoted the migration and invasion of CRC cells [@B16]. In this work, we further identified that Fpr1 SNP was associated with the distant metastasis of CRC. Fpr1 SNPs were also associated with the expression of P53, CEA, HER2 and Ki67. This is the first study to evaluate polymorphisms of Fpr1 in CRC and find positive correlations. Further replication study with a larger sample size is required. Additionally, research on interaction mechanism between Fpr1 SNPs and the positive related factors is needed.
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:   single nucleotide polymorphisms

CEA

:   carcino-embryonic antigen

###### 

Allele frequencies in the CRC patients studied

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference ID   SNP     Allele     Phenotype   Frequency                                                                              
  -------------- ------- ---------- ----------- ---------------------- -------------------------------- ------------------------------ ----------------------
                                                Chinese CRC patients   CHB\* (Han Chinese in Beijing)   CHS\* (Southern Han Chinese)   CH^\#^ (Han Chinese)

  rs78488639     L97M    c.289C\    Leu^97^\    0.885\                 0.918\                           0.938\                         None
                         c.289A     Met^97^     0.115                  0.082                            0.062                          

  rs2070745      V101L   c.301G\    Val^101^\   0.552\                 0.549\                           0.529\                         0.550\
                         c.301C     Leu^101^    0.448                  0.451                            0.471                          0.450

  rs28930680     F102F   c.306T\    Phe^102^\   0.969\                 0.971\                           0.981\                         None
                         c.306C     Phe^102^    0.031                  0.029                            0.019                          

  rs2070746      P182P   c.546C\    Pro^182^\   0.500\                 0.524\                           0.486\                         None
                         c.546A     Pro^182^    0.500                  0.476                            0.514                          

  rs5030880      R190W   c.568A\    Arg^190^\   0.865\                 0.791\                           0.824\                         0.828\
                         c.568T     Trp^190^    0.135                  0.209                            0.176                          0.172

  rs1042229      N192K   c.576T\    Asn^192^\   0.521\                 0.524\                           0.567\                         0.514\
                         c.576G\    Lys^192^\   0.344\                 0.262\                           0.262\                         0.304\
                         c.576C     Asn^192^    0.135                  0.214                            0.171                          0.182

  rs867228       A346E   c.1037C\   Ala^346^\   0.656\                 0.714\                           0.705\                         0.703\
                         c.1037A    Glu^346^    0.344                  0.286                            0.295                          0.297
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

\*Data from the HapMap resource (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>); ^\#^Data from Zhou\'s report [@B24].

###### 

Genotype frequencies in the CRC patients studied

  ------------------------------------------------------
  Reference ID   SNP     Genotype   Frequency   
  -------------- ------- ---------- ----------- --------
  rs78488639     L97M    L/L\       0.792\      None
                         L/M\       0.187\      
                         M/M        0.021       

  rs2070745      V101L   V/V\       0.271\      0.297\
                         V/L\       0.562\      0.507\
                         L/L        0.167       0.196

  rs28930680     F102F   F/F        1.000       None

  rs2070746      P182P   P/P        1.000       None

  rs5030880      R190W   R/R\       0.729\      0.689\
                         R/W\       0.271\      0.278\
                         W/W        0.000       0.033

  rs1042229      N192K   N/N\       0.458\      0.469\
                         N/K\       0.396\      0.455\
                         K/K        0.146       0.077

  rs867228       A346E   A/A\       0.396\      0.507\
                         A/E\       0.521\      0.392\
                         E/E        0.083       0.100
  ------------------------------------------------------

^\#^Data from Zhou\'s report [@B24].

###### 

*Fpr1* SNPs with clinicopathological characteristics (c.289, c.301, and c.306)

  Parameters               Mutation of 289   *P* value   Mutation of 301   *P* value   Mutation of 306   *p* value                             
  ------------------------ ----------------- ----------- ----------------- ----------- ----------------- ----------- ---- ------- ---- --- --- -------
  **Gender**                                                                                                                                   
  Female                   25                4           1                 0.710       4                 22          4    0.008   26   4   0   1.000
  Male                     23                4           3                             11                10          9            27   3   0   
  **Age (years)**                                                                                                                              
  ≤ 60                     26                4           2                 1.000       5                 22          5    0.042   29   3   0   0.695
  \> 60                    22                4           2                             10                10          8            24   4   0   
  **AJCC**                                                                                                                                     
  0-II                     24                6           0                 0.057       6                 18          6    0.621   23   7   0   0.011
  III-IV                   24                2           4                             9                 14          7            30   0   0   
  **Tumor location**                                                                                                                           
  Colon                    26                7           3                 0.170       7                 21          8    0.474   30   6   0   0.225
  Rectum                   22                1           1                             8                 11          5            23   1   0   
  **Size of tumor**                                                                                                                            
  ≤ 5                      29                5           0                 0.064       6                 24          4    0.198   27   7   0   0.016
  \> 5                     19                3           4                             9                 18          9            26   0   0   
  **Differentiation**                                                                                                                          
  I-II                     25                2           4                 0.057       4                 23          4    0.004   27   4   0   1.000
  III-IV                   23                6           0                             11                9           9            26   3   0   
  **Lymphatic invasion**                                                                                                                       
  Yes                      21                6           1                 0.202       5                 19          4    0.108   24   4   0   0.695
  No                       27                2           3                             10                13          9            29   3   0   
  **Distant Metastasis**                                                                                                                       
  Yes                      5                 1           4                 0.001       2                 8           0    0.121   7    3   0   0.083
  No                       43                7           0                             13                24          13           46   4   0   
  **Pathological Type**                                                                                                                        
  Adenocarcinoma           35                6           2                 0.659       8                 25          10   0.222   39   4   0   0.393
  Mucinous                 13                2           2                             7                 7           3            14   3   0   

###### 

*Fpr1* SNPs with clinicopathological characteristics (c.546, c.568, and c.1037)

  Parameters               Mutation of 546   *P* value   Mutation of 568   *p* value   Mutation of 1037   *p* value                             
  ------------------------ ----------------- ----------- ----------------- ----------- ------------------ ----------- --- ------- ---- ---- --- -------
  **Gender**                                                                                                                                    
  Female                   7                 15          8                 1.000       20                 10          0   1.000   11   15   4   1.000
  Male                     8                 15          7                             21                 9           0           12   14   4   
  **Age (years)**                                                                                                                               
  ≤ 60                     5                 17          10                0.206       27                 5           0   0.006   15   12   5   0.218
  \> 60                    10                13          5                             14                 14          0           8    17   3   
  **AJCC**                                                                                                                                      
  0-II                     9                 12          9                 0.283       21                 9           0   1.000   10   17   3   0.514
  III-IV                   6                 18          6                             20                 10          0           13   12   5   
  **Tumor location**                                                                                                                            
  Colon                    8                 18          10                0.742       24                 12          0   0.784   19   17   0   0.000
  Rectum                   7                 12          5                             17                 7           0           4    12   8   
  **Size of tumor**                                                                                                                             
  ≤ 5                      8                 22          4                 0.012       32                 2           0   0.000   12   18   4   0.716
  \> 5                     7                 8           11                            9                  17          0           11   11   4   
  **Differentiation**                                                                                                                           
  I-II                     6                 20          5                 0.061       29                 2           0   0.000   13   18   0   0.005
  III-IV                   9                 10          10                            12                 17          0           10   11   8   
  **Lymphatic invasion**                                                                                                                        
  Yes                      7                 18          3                 0.043       20                 8           0   0.782   12   12   4   0.724
  No                       8                 12          12                            21                 11          0           11   17   4   
  **Distant Metastasis**                                                                                                                        
  Yes                      4                 4           2                 0.550       7                  3           0   1.000   6    4    0   0.241
  No                       11                26          13                            34                 16          0           17   25   8   
  **Pathological Type**                                                                                                                         
  Adenocarcinoma           11                23          9                 0.562       36                 7           0   0.000   19   20   4   0.208
  Mucinous                 4                 7           6                             5                  12          0           4    9    4   

###### 

*Fpr1* SNPs with clinicopathological characteristics (c.576)

  ---------------------------------------------------------------------------------
  Parameters               Mutation of 576 n (%)   *p*\                     
                                                   value                    
  ------------------------ ----------------------- ------- ---- --- --- --- -------
  **Gender**                                                                

  Female                   9                       6       9    0   4   2   0.463

  Male                     7                       5       9    0   2   7   

  **Age (years)**                                                           

  ≤ 60                     12                      2       10   0   4   4   0.053

  \> 60                    4                       9       8    0   2   5   

  **AJCC**                                                                  

  0-II                     9                       5       6    0   3   7   0.282

  III-IV                   7                       6       12   0   3   2   

  **Tumor location**                                                        

  Colon                    9                       7       12   0   3   5   0.937

  Rectum                   7                       4       6    0   3   4   

  **Size of tumor**                                                         

  ≤ 5                      8                       6       12   0   2   6   0.628

  \> 5                     8                       5       6    0   4   3   

  **Differentiation**                                                       

  I-II                     9                       6       9    0   3   4   0.982

  III-IV                   7                       5       9    0   3   5   

  **Lymphatic invasion**                                                    

  Yes                      6                       6       10   0   3   3   0.734

  No                       10                      5       8    0   3   6   

  **Distant Metastasis**                                                    

  Yes                      2                       2       2    0   2   2   0.688

  No                       14                      9       16   0   4   7   

  **Pathological Type**                                                     

  Adenocarcinoma           14                      9       5    0   6   9   0.000

  Mucinous                 2                       2       13   0   0   0   
  ---------------------------------------------------------------------------------

###### 

Fpr1 SNPs with specific diagnostic markers of CRC

  ---------------------------------------------------------------------------------------------------------------------------
  Parameters\         P53   *p* value   CEA     *p* value   HER-2   *p* value   Ki-67   *p* value                     
  (Total mutations)                                                                                                   
  ------------------- ----- ----------- ------- ----------- ------- ----------- ------- ----------- ------- ---- ---- -------
  **c.289**                             0.004                       0.030                           0.001             0.034

  C/C                 39    9                   43          5                   30      18                  30   18   

  C/A                 3     5                   5           3                   0       8                   8    0    

  A/A                 1     3                   2           2                   1       3                   4    0    

  **c.301**                             0.409                       0.429                           0.277             0.060

  G/G                 9     6                   11          4                   5       10                  14   1    

  G/C                 25    7                   28          4                   18      14                  20   12   

  C/C                 9     4                   11          2                   8       5                   8    5    

  **c.306**                             0.092                       0.011                           0.247             1.000

  T/T                 40    13                  47          6                   29      24                  37   16   

  T/C                 3     4                   3           4                   2       5                   5    2    

  C/C                 0     0                   0           0                   0       0                   0    0    

  **c.546**                             0.188                       0.283                           0.006             0.090

  C/C                 11    4                   12          3                   13      2                   7    8    

  C/A                 24    6                   27          3                   13      17                  24   6    

  A/A                 8     7                   11          4                   5       10                  11   4    

  **c.568**                             1.000                       0.711                           0.100             1.000

  G/G                 29    12                  35          6                   18      23                  29   12   

  G/C                 14    5                   15          4                   13      6                   13   6    

  C/C                 0     0                   0           0                   0       0                   0    0    

  **c.1037**                            0.851                       0.714                           0.936             0.676

  T/T                 17    6                   19          4                   11      12                  15   8    

  T/C                 21    8                   25          4                   16      13                  22   7    

  C/C                 5     3                   6           2                   4       4                   5    3    

  **c.576**                             0.008                       0.557                           0.001             0.011

  T/T                 7     9                   11          5                   5       11                  13   3    

  T/C                 10    1                   10          1                   8       3                   10   1    

  T/G                 14    4                   16          2                   5       13                  14   4    

  C/C                 0     0                   0           0                   0       0                   0    0    

  C/G                 3     3                   5           1                   4       2                   2    4    

  G/G                 9     0                   8           1                   9       0                   3    6    
  ---------------------------------------------------------------------------------------------------------------------------

[^1]: \*These authors contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
